BIIB
Biogen Inc.HealthcareDrug Manufacturers - GeneralRisk-First
$199.00 · 15min delay
β 0.20A steady large-cap risk-flagged situation trading at a premium valuation.
52-wk low $119.1852-wk high $202.41
Mkt Cap
$29.38B
P/E
—
PEG
3.94
P/B
1.57
Dividend
—
ROE
7.7%
About the business
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Who would buy BIIB?
Consensus 27/100 · Aligned · Investors mostly agree.
2 9 4
Endorses
· 2 frameworks- Howard Marks· Marks Risk-First83/100
Debt/Equity < 0.5 0.35 clears "< 0.50".
- Dividend Growth School· Dividend Income80/100
Payout Ratio < 70% 0.0% clears "< 70.0%".
Rejects
· 3 frameworks- Joel Greenblatt
Insider activity · Mixed
Open-market buying concentrated in one insider
Strength 35/100
Buying is limited to a single filer (MURPHY NICOLE, $585). Single-insider buys are worth noting but carry less weight than broad-based conviction — they can reflect an outlier view rather than a shared read inside the C-suite. Over the 6M window, insiders are net buyers by 84,208 shares.
- Buying concentrated in one filer — lower conviction signal.
In Prism's context
Insider activity is inconclusive here. The stock's case should lean on the framework verdict (Fails criteria, score 27/100) and the archetype read (Risk-First).
| Insider | Role | Type | Date | Shares | Avg price | Value | Own |
|---|---|---|---|---|---|---|---|
| KEENEY ADAM JAMES | Officer | Transaction | May 1, 2026 | 939 | — | — | Direct |
| GODBOUT SEAN | Officer | Transaction | Apr 1, 2026 | 181 | — | — | Direct |
| MURPHY NICOLE | Officer | Open-market buy | Feb 12, 2026 | 3 | $195.00 | $585 | Direct |
| SINGHAL PRIYA | Officer | Open-market sell | Feb 9, 2026 | 2,660 | $199.83 | $532K | Direct |
| IZZAR RACHID | Officer | Transaction | Feb 6, 2026 | 6,889 | — | — | Direct |
| MURPHY NICOLE | Officer | Transaction | Feb 6, 2026 | 8,725 | — | — | Direct |
| KEENEY ADAM JAMES | Officer | Transaction | Feb 6, 2026 | 5,080 | — | — | Direct |
| GROGAN JANE | Officer | Transaction | Feb 6, 2026 | 3,258 | — | — | Direct |
| GODBOUT SEAN | Officer | Transaction | Feb 6, 2026 | 1,079 | — | — | Direct |
| ALEXANDER SUSAN H | Officer | Transaction | Feb 6, 2026 | 9,046 | — | — | Direct |
| GREGORY GINGER | Officer | Transaction | Feb 6, 2026 | 7,183 | — | — | Direct |
| KRAMER ROBIN C. | Chief Financial Officer | Transaction | Feb 6, 2026 | 5,003 | — | — | Direct |
| SINGHAL PRIYA | Officer | Transaction | Feb 6, 2026 | 6,900 | — | — | Direct |
| VIEHBACHER CHRISTOPHER | Chief Executive Officer | Transaction | Feb 6, 2026 | 24,461 | — | — | Direct |
| SINGHAL PRIYA | Officer | Open-market sell | Feb 2, 2026 | 748 | $179.30 | $134K | Direct |
| SINGHAL PRIYA | Officer | Transaction | Jan 30, 2026 | 1,829 | — | — | Direct |
| VIEHBACHER CHRISTOPHER | Chief Executive Officer | Transaction | Dec 1, 2025 | 7,040 | — | — | Direct |
Insider activity from Yahoo Finance (quoteSummary: insiderTransactions + netSharePurchaseActivity). Cached 6 hours. · Insiders hold 0.2% of shares outstanding.
Net 6M: +84,208 sh
Price history
—
Loading…
Drag across the chart to select a custom period — all analysis below refocuses to that window.
What this means: Price near 52-week highs despite weak framework scores — market enthusiasm is running ahead of the fundamentals most legends look at.
What would BIIB do to your portfolio?
Add Biogen Inc. at a hypothetical weight and Prism recalculates your whole book:
Risk metrics
Sharpe, Sortino, volatility, max drawdown, beta — before and after.
Sector concentration
How much this shifts your top sector weight and overall diversification.
Archetype tilt
Whether this leans your book more toward Quality, Value, Growth, Deep Value, Income, or Momentum.
BIIB is currently tagged:Risk-FirstFails criteria (27/100)
Portfolio analytics are part of the member experience.
Sign in to run this simulationProbabilistic recommendation· rec-v1.0.0-2026-04
Biogen Inc. · BIIB
BIIB: 59% estimated probability of outperforming over the next 12M window. 4 of 6 signal families positive (high confidence). Strongest support: Reverse DCF: low expectations bar. Main risk to monitor: Net insider selling ($2.8M).
Outperform prob.
59%
vs S&P 500 · 12M
Expected return
-1.0% → +23.0%
mid +11.0% / yr
Downside (p20)
-4.3%
stress -8.7%
Data quality
95/100
Excellent
Probabilistic research output, not financial advice. Prism recommendations are based on available data, historical relationships, and model assumptions. They do not guarantee future returns. Conduct independent due diligence before any investment decision.
Backtested and similar-setup statistics may be affected by survivorship bias, look-ahead bias, overfitting, transaction costs, liquidity constraints, and data limitations. Probability estimates are anchored heuristics — not validated forecasts — until the walk-forward backtest pipeline is in place.
Prism Score
Composite 75/100. Strongest contribution from valuation; weakest from ownership. Risk patterns shaved 2 points off the composite.
Composite
75
/ 100
Deep valueval.
85/ 100
P/B 1.57× · FCF yield 6.5%
Margin of safetyval.
63/ 100
3% below fair value
Bull · base · bear scenarios
Three plausible paths over a 5-year horizon.
Indicative only. Probabilities are model-implied weights for stress-testing — not forecasts.
Bull
~20%$267.23
+6.1% / yr (5y)
A turnaround takes hold: margin recovers toward peer averages, revenue stabilises, and the market re-prices the asset value rather than the running earnings.
Drivers
- • Margin expands by 200–400 bps from 23%
- • Stranded asset value crystallises
- • Multiple re-rates one full turn higher
Base
~45%$205.56
+0.7% / yr (5y)
No deterioration, no surprise re-acceleration. 23% operating margin and 2% top-line growth chug along; the multiple slowly converges to the central fair-value estimate.
Global value comparison
Biogen Inc. vs sector medians — GCC, MENA, and Global ex-US.
Sector: Healthcare. MENA-aware investors can sanity-check whether the US name is offering value relative to regional peers.
| Metric | BIIB | GCC median | MENA median | Global ex-US |
|---|---|---|---|---|
| P/E (TTM) | — | 24.0× | — | 20.0× |
| P/B | 1.57× | 4.80× | — | 3.80× |
| Dividend yield | — | 1.40% | — | 1.80% |
| ROE | 7.7% |
Earnings reaction explainer
BIIB blew past estimates by 76.5%.
Reported EPS $3.57 vs $2.02 expected — well outside the normal beat-and-raise band. The market typically rewards a print this size only if it is read as durable, not one-off. Trailing operating margin: 22.9%.
- Growth investorsPositive
Confirms operating leverage — 31% trailing EPS growth + a beat of this size is the pattern that drives multi-year re-rates.
- Quality investorsPositive
If ROE (8%) and operating margin (23%) are stable or rising, the beat is consistent with compounding rather than one-off.
- Value investorsNegative
Outsized beats on thin trailing quality often invite multiple expansion that doesn't survive the next print.
News & events
Next earnings
Thu, Jul 30 · consensus EPS $2.02 · last actual $3.57
Is Biogen Inc. (BIIB) one of the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen?
Insider Monkey · just now
Assessing Biogen (BIIB) Valuation After Recent Share Price Momentum And Mixed Long Term Returns
Simply Wall St. · just now
3 Value Stocks We Approach with Caution
StockStory · just now
Key Metrics at a Glance
P/E Ratio (TTM)
N/A
PEG Ratio
3.94
P/B Ratio
1.57
EPS Growth
31.1%
Revenue Growth
1.9%
Debt / Equity
0.35
Net Cash / Share
$-15.44
Return on Equity
7.7%
Gross Margin
78.7%
Operating Margin
22.9%
FCF / Share
$12.98
Current Ratio
3.06